期刊文献+

Use of portal pressure studies in the management of variceal haemorrhage 被引量:39

Use of portal pressure studies in the management of variceal haemorrhage
在线阅读 下载PDF
导出
摘要 Portal hypertension occurs as a complication of liver cirrhosis and complications such as variceal bleeding lead to significant demands on resources. Endoscopy is the gold standard method for screening cirrhotic patients however universal endoscopic screening may mean a lot of unnecessary procedures as the presence of oesophageal varices is variable hence a large time and cost burden on endoscopy units to carry out both screening and subsequent follow up of variceal bleeds. A less invasive method to identify those at high risk of bleeding would allow earlier prophylactic measures to be applied. Hepatic venous pressure gradient (HVPG) is an acceptable indirect measurement of portal hypertension and predictor of the complications of portal hypertension in adult cirrhotics. Varices develop at a HVPG of 10-12 mmHg with the appearance of other complications with HPVG > 12 mmHg. Variceal bleeding does not occur in pressures under 12 mmHg. HPVG > 20 mmHg measured early after admission is a significant prognostic indicator of failure to control bleeding varices, indeed early transjugular intrahepatic portosystemic shunt (TIPS) in such circumstances reduces mortality significantly. HVPG can be used to identify responders to medical therapy. Patients who do not achieve the suggested reduction targets in HVPG have a high risk of rebleeding despite endoscopic ligation and may not derive significant overall mortality benefit from endoscopic intervention alone, ultimately requiring TIPS or liver transplantation. Early HVPG measurements following a variceal bleed can help to identify those at risk of treatment failure who may benefit from early intervention with TIPS. Therefore, we suggest using HVPG measurement as the investigation of choice in those with confirmed cirrhosis in place of endoscopy for intitial variceal screening and, where indicated, a trial of B-blockade, either intravenously during the initial pressure study with assessment of response or oral therapy with repeat HVPG six weeks later. In those with elevated pressures, primary medical prophylaxis could be commenced with subsequent close monitoring of HVPG thus negating the need for endoscopy at this point. All patients presenting with variceal haemorrhage should undergo HVPG measurement and those with a gradient greater than 20 mmHg should be considered for early TIPS. By introducing portal pressure studies into a management algorithm for variceal bleeding, the number of endoscopies required for further intervention and follow up can be reduced leading to significant savings in terms of cost and demand on resources. Portal hypertension occurs as a complication of liver cirrhosis and complications such as variceal bleeding lead to significant demands on resources. Endoscopy is the gold standard method for screening cirrhotic patients however universal endoscopic screening may mean a lot of unnecessary procedures as the presence of oesophageal varices is variable hence a large time and cost burden on endoscopy units to carry out both screening and subsequent follow up of variceal bleeds. A less invasive method to identify those at high risk of bleeding would allow earlier prophylactic measures to be applied. Hepatic venous pressure gradient (HVPG) is an acceptable indirect measurement of portal hypertension and predictor of the complications of portal hypertension in adult cirrhotics. Varices develop at a HVPG of 10-12 mmHg with the appearance of other complications with HPVG > 12 mmHg. Variceal bleeding does not occur in pressures under 12 mmHg. HPVG > 20 mmHg measured early after admission is a significant prognostic indicator of failure to control bleeding varices, indeed early transjugular intrahepatic portosystemic shunt (TIPS) in such circumstances reduces mortality significantly. HVPG can be used to identify responders to medical therapy. Patients who do not achieve the suggested reduction targets in HVPG have a high risk of rebleeding despite endoscopic ligation and may not derive significant overall mortality benefit from endoscopic intervention alone, ultimately requiring TIPS or liver transplantation. Early HVPG measurements following a variceal bleed can help to identify those at risk of treatment failure who may benefit from early intervention with TIPS. Therefore, we suggest using HVPG measurement as the investigation of choice in those with confirmed cirrhosis in place of endoscopy for intitial variceal screening and, where indicated, a trial of B-blockade, either intravenously during the initial pressure study with assessment of response or oral therapy with repeat HVPG six weeks later. In those with elevated pressures, primary medical prophylaxis could be commenced with subsequent close monitoring of HVPG thus negating the need for endoscopy at this point. All patients presenting with variceal haemorrhage should undergo HVPG measurement and those with a gradient greater than 20 mmHg should be considered for early TIPS. By introducing portal pressure studies into a management algorithm for variceal bleeding, the number of endoscopies required for further intervention and follow up can be reduced leading to significant savings in terms of cost and demand on resources.
出处 《World Journal of Gastrointestinal Endoscopy》 CAS 2012年第7期281-289,共9页 世界胃肠内镜杂志(英文版)(电子版)
关键词 Variceal HAEMORRHAGE PORTAL hypertension PORTAL PRESSURE VARICES HEPATIC VENOUS PRESSURE gradient Variceal haemorrhage Portal hypertension Portal pressure Varices Hepatic venous pressure gradient
  • 相关文献

参考文献61

  • 1Abraldes J G,,Bosch J.Somatostatin and analogues in portal Hyper-tension. Hepatology . 2002
  • 2Winkfield,B,Aube,C,Burtin,P.Inter-observer and intra-observer variability in hepatology. European Journal of Gastroenterology and Hepatology . 2003
  • 3Pascal JP,Cale s P,Desmorat H.Natural history of oesophageal varices. Recent advances in the pathophysiology and treatment of portal hypertension . 1989
  • 4Bureau C,Peron JM,Alric L,et al."A la carte"treatment of portal hypertension:adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology . 2002
  • 5D. L. Raines, A. W. Dupont&#8224,</a> &amp,M. R. Arguedas.Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding. Alimentary Pharmacology and Therapeutics . 2004
  • 6Bosch J,Abraldes JG,Groszmann R.Current management of portal hypertension. Journal of Hepatology . 2003
  • 7Merkel C,Bolognesi M,Sacerdoti D,et al.The hemodynamicresponse to medical treatment of portal hypertension as a pre-dictor of clinical ffectiveness in the primary prophylaxis ofvariceal bleeding in cirrhosis. Hepatology . 2000
  • 8Vorobioff J,Bredfeldt JE,Groszmann RJ.Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. American Journal of Physiology . 1983
  • 9Benoit JN,Barrowman JA,Harper SL,et al.Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. American Journal of Physiology . 1984
  • 10Schepis F,Camma C,Niceforo D,et al.Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?. Hepatology . 2001

共引文献10

同被引文献261

引证文献39

二级引证文献257

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部